Imunon price to sales ratio IMNN

Market value divided by revenue over the last twelve months, since 2019.

Today, Oct 23, 2026: n/m; not a meaningful number
Last meaningful: 22.4×; Aug 2023
8-year median: 63.5×
8-year range: 19.6× to 192×
Peer median: 1.4×

Imunon's price to sales ratio is not a meaningful number today: revenue for one or more of the four quarters through 2026-06-30 is missing, so twelve months can't be added up.

It was last meaningful in Aug 2023, at 22.4×.

On the days it had one over the last 8 years, its median was 63.5×, from 19.6× in Mar 2023 to 192× in Jul 2021.

Price to sales ratio over time

Open the interactive chart, with overlays and comparisons

Year by year

Year	End of year	Low	High
2023	22.4×	19.6×	25.5×
2022	20.1×	19.7×	90.0×
2021	93.5×	63.6×	192×
2020	53.1×	31.2×	179×
2019	74.2×	56.0×	93.1×

Against its peers

Companies in Healthcare nearest Imunon's size, closest first, today.

Company	Price to sales ratio
IMNNImunon	n/m
NEPHNephros	1.9×
ATNMActinium Pharmaceuticals	n/m
APTAlpha Pro Tech	0.9×
SPROSpero Therapeutics	1.4×
Peer median	1.4×

What the price to sales ratio tells you

Market value divided by revenue over the last twelve months. Useful for companies with little or no profit yet, since sales are harder to make negative than earnings.

Ignores margins entirely. A software company at 10× sales with 30% margins can be cheaper than a grocer at 1× sales with 2% margins.

More on Imunon

Valuation data, not investment advice. Prices as of Oct 23, 2026. Reported figures come from the company's filings with the SEC.